Concepts (124)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 12 | 2015 | 87 | 1.170 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2011 | 337 | 0.750 |
Why?
|
| Fallopian Tube Neoplasms | 3 | 2014 | 7 | 0.620 |
Why?
|
| Peritoneal Neoplasms | 4 | 2014 | 241 | 0.570 |
Why?
|
| Topotecan | 3 | 2010 | 15 | 0.510 |
Why?
|
| Endometrial Neoplasms | 5 | 2004 | 34 | 0.450 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2011 | 401 | 0.390 |
Why?
|
| Antineoplastic Agents | 5 | 2007 | 546 | 0.370 |
Why?
|
| Carboplatin | 3 | 2011 | 40 | 0.340 |
Why?
|
| Hyperthermia, Induced | 3 | 2011 | 235 | 0.340 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2012 | 142 | 0.260 |
Why?
|
| Vesicovaginal Fistula | 1 | 2005 | 4 | 0.260 |
Why?
|
| Hysterectomy, Vaginal | 1 | 2005 | 6 | 0.260 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2005 | 41 | 0.250 |
Why?
|
| Vulvar Neoplasms | 2 | 2012 | 6 | 0.220 |
Why?
|
| Middle Aged | 20 | 2016 | 10829 | 0.220 |
Why?
|
| Tomography, Emission-Computed | 1 | 2002 | 25 | 0.220 |
Why?
|
| Aged | 19 | 2016 | 9487 | 0.210 |
Why?
|
| Lymph Nodes | 2 | 2012 | 92 | 0.210 |
Why?
|
| Female | 24 | 2016 | 18164 | 0.200 |
Why?
|
| Carcinoma | 1 | 2002 | 87 | 0.200 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2010 | 10 | 0.190 |
Why?
|
| Paclitaxel | 3 | 2011 | 50 | 0.180 |
Why?
|
| Adult | 15 | 2016 | 8420 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2014 | 89 | 0.160 |
Why?
|
| Humans | 24 | 2016 | 29093 | 0.160 |
Why?
|
| Infusions, Parenteral | 4 | 2014 | 64 | 0.150 |
Why?
|
| Cisplatin | 4 | 2005 | 69 | 0.150 |
Why?
|
| Neoplasm Staging | 5 | 2014 | 436 | 0.140 |
Why?
|
| Ovarian Diseases | 1 | 2015 | 8 | 0.130 |
Why?
|
| Drug Administration Schedule | 4 | 2010 | 246 | 0.130 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2012 | 69 | 0.130 |
Why?
|
| Serum Albumin | 1 | 2015 | 53 | 0.130 |
Why?
|
| Antibodies, Bispecific | 1 | 2014 | 6 | 0.130 |
Why?
|
| Ascites | 1 | 2014 | 13 | 0.130 |
Why?
|
| Combined Modality Therapy | 4 | 2011 | 525 | 0.120 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2006 | 32 | 0.120 |
Why?
|
| Postural Balance | 1 | 2016 | 160 | 0.120 |
Why?
|
| Calcium | 1 | 2015 | 296 | 0.120 |
Why?
|
| Pesticides | 1 | 2016 | 189 | 0.120 |
Why?
|
| Occupational Exposure | 1 | 2016 | 224 | 0.110 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 235 | 0.110 |
Why?
|
| Transients and Migrants | 1 | 2016 | 281 | 0.110 |
Why?
|
| Peritoneum | 1 | 2011 | 24 | 0.100 |
Why?
|
| Albumins | 1 | 2011 | 38 | 0.100 |
Why?
|
| Nanoparticles | 1 | 2011 | 47 | 0.100 |
Why?
|
| Hispanic Americans | 1 | 2016 | 904 | 0.090 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2011 | 146 | 0.090 |
Why?
|
| Aged, 80 and over | 8 | 2012 | 3717 | 0.080 |
Why?
|
| Hematologic Diseases | 1 | 2007 | 23 | 0.080 |
Why?
|
| Lymph Node Excision | 3 | 2012 | 89 | 0.070 |
Why?
|
| Carcinosarcoma | 1 | 2005 | 3 | 0.070 |
Why?
|
| Mixed Tumor, Mesodermal | 1 | 2005 | 2 | 0.070 |
Why?
|
| Dysgerminoma | 1 | 2004 | 1 | 0.070 |
Why?
|
| Uterine Neoplasms | 1 | 2005 | 23 | 0.060 |
Why?
|
| Chromium Compounds | 1 | 2003 | 1 | 0.060 |
Why?
|
| Phosphates | 1 | 2003 | 25 | 0.060 |
Why?
|
| Danazol | 1 | 2003 | 1 | 0.060 |
Why?
|
| Estrogen Antagonists | 1 | 2003 | 14 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2003 | 55 | 0.060 |
Why?
|
| Oligopeptides | 1 | 2003 | 51 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2015 | 3111 | 0.060 |
Why?
|
| Acridines | 1 | 2002 | 19 | 0.050 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2002 | 20 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2005 | 3099 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2002 | 56 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2002 | 64 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2002 | 87 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2010 | 440 | 0.050 |
Why?
|
| Pelvis | 2 | 2015 | 61 | 0.050 |
Why?
|
| Melanoma | 1 | 2002 | 148 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2012 | 2019 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2002 | 206 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2005 | 163 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 2108 | 0.040 |
Why?
|
| Disease-Free Survival | 3 | 2003 | 281 | 0.040 |
Why?
|
| Survival Rate | 2 | 2014 | 795 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2005 | 85 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 493 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 859 | 0.030 |
Why?
|
| Neutropenia | 2 | 2003 | 23 | 0.030 |
Why?
|
| Groin | 1 | 2012 | 5 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 156 | 0.030 |
Why?
|
| North Carolina | 1 | 2016 | 1423 | 0.030 |
Why?
|
| Mitomycin | 1 | 2011 | 45 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 38 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 1362 | 0.020 |
Why?
|
| Temperature | 1 | 2010 | 55 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2011 | 332 | 0.020 |
Why?
|
| Adolescent | 2 | 2010 | 3254 | 0.020 |
Why?
|
| Quality of Life | 1 | 2014 | 816 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2010 | 189 | 0.020 |
Why?
|
| Incidence | 1 | 2012 | 1119 | 0.020 |
Why?
|
| Registries | 1 | 2010 | 278 | 0.020 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2006 | 3 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2006 | 98 | 0.020 |
Why?
|
| Hysterectomy | 1 | 2006 | 37 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2005 | 4 | 0.020 |
Why?
|
| Etoposide | 1 | 2004 | 30 | 0.020 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2003 | 2 | 0.020 |
Why?
|
| Phosphorus Radioisotopes | 1 | 2003 | 4 | 0.020 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2003 | 4 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2003 | 41 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2003 | 25 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2004 | 35 | 0.020 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2003 | 20 | 0.010 |
Why?
|
| Tamoxifen | 1 | 2004 | 48 | 0.010 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2004 | 89 | 0.010 |
Why?
|
| Depsipeptides | 1 | 2003 | 1 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 2003 | 45 | 0.010 |
Why?
|
| Organoplatinum Compounds | 1 | 2003 | 42 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2003 | 89 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 2402 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 301 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2004 | 199 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2002 | 4 | 0.010 |
Why?
|
| Intercalating Agents | 1 | 2002 | 8 | 0.010 |
Why?
|
| Vomiting | 1 | 2002 | 24 | 0.010 |
Why?
|
| Remission Induction | 1 | 2002 | 78 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2002 | 118 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 162 | 0.010 |
Why?
|
| Disease Progression | 1 | 2003 | 572 | 0.010 |
Why?
|
| Male | 1 | 2016 | 17807 | 0.010 |
Why?
|
| Child | 1 | 2004 | 2219 | 0.010 |
Why?
|